BPC-157 capsules and BPC-157 vials contain the same peptide — the difference is format, not molecule. The vials are lyophilized powder requiring reconstitution and yielding whatever concentration the laboratory prepares; the capsules deliver a fixed 500 micrograms of the same solid-phase-synthesised, HPLC-purified material with no preparation step at all. In a BPC-157 capsules vs BPC-157 comparison, the real question is which format matches the administration route your model uses and how much preparation variability you can tolerate.
We stock BPC-157 capsules at 500 mcg per capsule in 30 and 60 count bottles, and BPC-157 vials in 5, 10, 15 and 20 mg sizes, both covered by lot-matched HPLC certificates at 99% purity or better. Both are research chemicals for in-vitro and preclinical laboratory work only, not for human or veterinary use.
BPC-157 capsules vs BPC-157 vials at a glance
| Attribute | BPC-157 Capsules | BPC-157 Vials |
|---|---|---|
| Peptide | Identical — same synthesis, same purity specification | Identical — same synthesis, same purity specification |
| Physical form | Solid capsule, peptide blended with an inert carrier | Lyophilized powder in a sealed, stoppered glass vial |
| Quantity per unit | 500 mcg fixed per capsule | Whole vial contents; concentration set at reconstitution |
| Preparation required | None | Reconstitution with bacteriostatic or sterile water |
| Preparation error risk | Eliminated — no measuring step | Present — diluent volume, transfer loss, mixing |
| Route in published models | Oral and intragastric administration | Parenteral routes; also in-vitro application |
| Suitable for cell culture | No — capsule carrier is not designed for it | Yes — the standard choice |
| Concentration flexibility | None — fixed at 500 mcg | Full — any concentration within solubility |
| Pack sizes | 500 mcg × 30, 500 mcg × 60 | 5 mg, 10 mg, 15 mg, 20 mg |
| Total peptide per pack | 15 mg (30 count), 30 mg (60 count) | 5–20 mg per vial |
| Once opened | Bottle remains a dry solid; unopened capsules unaffected | Reconstituted solution has a finite working life |
| Purity | ≥99% HPLC, lot-matched COA | ≥99% HPLC, MS identity, lot-matched COA |
Why an oral BPC-157 format exists at all
Most research peptides make poor oral candidates. Gastric acid and intestinal proteases degrade them, and the intact molecule rarely survives to cross the epithelium, which is why the great majority of the peptide catalogue ships as lyophilized powder for parenteral or in-vitro use. BPC-157 is one of the exceptions, and the reason is where it came from: its parent, body protection compound, was characterised in human gastric juice. Stability work reports that the 15-residue fragment tolerates acidic aqueous conditions considerably better than most peptides of comparable length.
That is why the published gastrointestinal literature on BPC-157 includes oral and intragastric administration routes rather than relying solely on injection. An oral capsule format is therefore not a marketing convenience layered onto an injectable molecule — it corresponds to an administration route that actually appears in the research record. Our piece on oral peptide formats covers why that is unusual, and our oral formats guide covers the format landscape more generally.
A caveat belongs alongside that: acid tolerance is not the same as demonstrated systemic bioavailability. Surviving the stomach is a necessary condition, not a sufficient one, and the literature is stronger on local gastrointestinal effects than on quantified systemic exposure after oral administration. A study design that assumes an oral route produces the same systemic exposure as a parenteral one is assuming something the published record does not establish.
What actually changes between the two formats
Preparation variability
Every reconstitution introduces error: the diluent volume actually delivered, peptide left adhering to the vial or the transfer device, incomplete dissolution of the cake, and the compounding effect of serial dilutions. A capsule removes all of it. Across a 60-capsule bottle, the quantity per unit is fixed and identical, which is a real advantage in studies with many time points or many animals where preparation is otherwise repeated dozens of times.
Flexibility
That fixed quantity is also the capsule's limitation. A vial can be reconstituted to any concentration within the peptide's solubility, aliquoted, diluted for a concentration–response series and applied directly to cells. A capsule cannot do any of that. Anything requiring a graded concentration series or in-vitro application needs the vial format — see our reconstitution guide for the calculations involved.
Working life after opening
A reconstituted vial has a finite working life: once in solution the peptide is exposed to hydrolysis, microbial ingress if a non-preserved diluent was used, and losses from repeated freezing and thawing. A capsule bottle is a dry solid throughout, so an unused capsule at the end of a study is in the same condition as it was on day one. For long protocols with intermittent sampling, this is often the more consequential difference.
Which to choose for which research question
Choose capsules for oral-route and fixed-unit designs
If the model uses oral or intragastric administration — gastrointestinal preparations in particular, where the published record supports that route — capsules are the format that corresponds to it. They are also the practical choice for long multi-animal or multi-time-point protocols where preparation consistency matters more than concentration flexibility, and for laboratories without the equipment or aseptic space to reconstitute reliably.
Choose vials for in-vitro work and concentration series
Cell culture, receptor and signalling assays, concentration–response curves, parenteral-route animal work and any design needing a specific molar concentration all require the vial. Vials are also the only format that supports co-preparation with another peptide from a shared stock, and the only one from which an aliquot can be sent for independent verification.
Run both when route is the variable
The most interesting use of the pair is comparing routes directly. Because the peptide is identical between formats, an oral arm using capsules and a parenteral arm using reconstituted vial material differ in route and nothing else — a cleaner route comparison than most peptides permit. Related format variants extend that design further: BPC-157 arginate capsules use a salt form selected for oral work, troches target the sublingual route, and a nasal preparation covers the intranasal route.
Quantity accounting and cost per milligram
The two formats are priced and packaged on different logics, and comparing them requires converting to a common basis. A 30-capsule bottle at 500 micrograms per capsule contains 15 mg of peptide in total; a 60-capsule bottle contains 30 mg. Vials are sold by their fill mass directly. Working in total milligrams rather than in units or vials is the only way to compare pack sizes meaningfully, and it also makes the planning arithmetic obvious: a protocol needing 40 units of 500 micrograms needs two 30-capsule bottles, not one.
One accounting caveat applies to both formats equally. Lyophilized synthetic peptides ship as salts with residual water, so labelled mass overstates net peptide, and the offset varies between lots. Any study reporting quantities precisely should anchor to the certificate rather than to the label.
Storage and handling differences
Vials follow the standard peptide protocol: sealed lyophilized vials held frozen, brought to room temperature before the stopper is pierced so moisture does not condense on cold powder, reconstituted by running diluent down the wall, dissolved without shaking and aliquoted so stock is not repeatedly frozen and thawed. Our storage guide covers the detail.
Capsules are simpler but not maintenance-free. The bottle is kept closed, cool and dry, and away from humidity — a hygroscopic capsule shell that takes up moisture can soften or stick, and moisture is the main degradation route for a dry peptide solid. Capsules do not need to be frozen and generally should not be moved in and out of a freezer repeatedly, since condensation on a cold bottle is exactly the exposure to avoid. Neither format should be decanted into unlabelled secondary containers; lot traceability depends on the original packaging.
Purity, identity and COA checks
Ask for the lot-matched certificate in both cases. For the vial, confirm HPLC purity with a visible chromatogram, a mass-spectrometric result matching the expected 1419.55 g/mol, and a lot number matching the vial label. For capsules, the certificate covers the peptide raw material used to fill them, so ask specifically which peptide lot the bottle was filled from — a certificate that cannot be tied to the bottle in hand is not traceability. BPC-157's Pro-Pro-Pro run makes deletion and truncation impurities more likely during synthesis, and these elute close to the main peak in both cases. Our COA guide explains what a complete document should contain.
Regulatory framing
Both formats are supplied as research chemicals for laboratory use only. BPC-157 is not an approved medicine in the United States and is not a dietary supplement; a capsule format does not change that status, and a capsule is not evidence of suitability for human consumption. The published evidence is preclinical — cultured cells and rodents. Nothing on this page is a protocol for human or veterinary use. For broader context see our gut-health research overview.